N,N'-bis(glycyl)-1,3-diaminopropane | 97849-48-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N,N'-bis(glycyl)-1,3-diaminopropane
• 英文别名: N,N'-diglycyl-1,3-propanediamine；N.N'-Diglycyl-propylendiamin；1,3-bis-glycylamino-propane；N.N'-Diglycyl-trimethylendiamin；1.3-Bis-aminoacetamino-propan；1,3-Bis-glycylamino-propan；N,N'-diglycyl-trimethylene-diamine；2-amino-N-[3-[(2-aminoacetyl)amino]propyl]acetamide
• CAS: 97849-48-4
• 化学式: C₇H₁₆N₄O₂
• 分子量: 188.23
• InChiKey: IMZCRELLNWFUTL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.6
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  110
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 氨 作用下， 生成 N,N'-bis(glycyl)-1,3-diaminopropane
  参考文献：
  名称：

  v.Braun; Dengel; Jacob, Chemische Berichte, 1937, vol. 70, p. 1000

  摘要：

  DOI：

文献信息

• Antibody drug conjugates and methods
  申请人：Gazzard J. Lewis

  公开号：US20070134243A1

  公开（公告）日：2007-06-14

  The invention relates to antibody drug conjugate (ADC) compounds represented by Formula I: Ab-(L-D) p I where one or more 1,8 bis-naphthalimide drug moieties (D) having Formulas IIa and IIb are covalently linked by a linker (L) to an antibody (Ab). The invention also relates to pharmaceutical compositions comprising an effective amount of a Formula I ADC for treatment of hyperproliferative disorders and other disorders. The invention also relates to methods for killing or inhibiting the multiplication of a tumor cell or cancer cell including administering to a patient an effective amount of a Formula I ADC.
• US7947839B2
  申请人：——

  公开号：US7947839B2

  公开（公告）日：2011-05-24
• [EN] MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF<br/>[FR] AGENTS THÉRAPEUTIQUES MODIFIÉS, CONJUGUÉS LIPIDE-PEPTIDE AGRAFÉS, ET COMPOSITIONS LES COMPRENANT
  申请人：CALIFORNIA INST BIOMEDICAL RES

  公开号：WO2015095406A1

  公开（公告）日：2015-06-25

  Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.